Synovial Sarcoma Registry / Biospecimen Repository

Status Recruiting

Clinical Trial Summary

The purpose of this study is to collect and store data and samples for future research to attempt to improve outcomes for patients with synovial sarcoma. The future research will involve various types of genetic testing. Participants will be asked to allow access to medical records and leftover tumor tissue and may be asked to give a blood or saliva sample. Participants will also be asked to completed questionnaires about their medical history and may be contacted every 6 to 12 months for updates for up to 10 years.

Clinical Trial Description

This study will enroll patients with a diagnosis of Synovial Sarcoma. Following consent, demographic, clinical, treatment and outcome data will be collected from an interview and/or online survey. This will include a request for contact information for the subject's treating hospitals/physicians and a release of records request to obtain medical records. At approximately 6-12 month intervals for up to 10 years after initial diagnosis and/or relapse, subjects and/or their treating hospitals may be contacted to provide updates on treatment and outcomes. Tumor samples may be collected from residual material obtained during clinically indicated procedures occurring before or after consent to this study. No additional material will be collected or procedures performed solely for the purpose of this study. Blood may be collected at the participant's local institution at the time of a clinically indicated blood draw and/or saliva or a buccal swab may be collected as a germline sample and for analysis of circulating free DNA (cfDNA) and/or circulating tumor cells (CTCs). Genetic testing may be performed on tumor and germline samples submitted by subjects. Results will only be returned if deemed clinically significant. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05910307
Study type	Observational [Patient Registry]
Source	Children's Hospital of Philadelphia
Contact	Lauren Gutstein
Phone	267-425-2029
Email	gutsteinl1@chop.edu
Status	Recruiting
Phase
Start date	June 12, 2023
Completion date	June 2033

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03399448` - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)	Phase 1
Terminated	`NCT01957709` - Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma	Early Phase 1
Not yet recruiting	`NCT06456359` - Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor	Phase 2
Withdrawn	`NCT04906876` - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas	Phase 2
Active, not recruiting	`NCT02869217` - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors	Phase 1
Completed	`NCT01674101` - Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy	N/A
Completed	`NCT03250325` - Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma	Phase 1/Phase 2
Recruiting	`NCT06094101` - Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)	Phase 1/Phase 2
Terminated	`NCT03520959` - A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)	Phase 3
Terminated	`NCT02683148` - DHEA in Synovial Sarcoma Patients	Phase 1
Recruiting	`NCT05642455` - SPEARHEAD-3 Pediatric Study	Phase 1/Phase 2
Active, not recruiting	`NCT04420975` - Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma	Phase 1
Recruiting	`NCT02983539` - Detection of Circulating Tumor Cells in Patients With Sarcomas
Recruiting	`NCT04028479` - The Registry of Oncology Outcomes Associated With Testing and Treatment
Active, not recruiting	`NCT03132922` - MAGE-A4ᶜ¹º³²T for Multi-Tumor	Phase 1
Terminated	`NCT04145700` - CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma	Phase 1/Phase 2
Completed	`NCT00004853` - Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy	Phase 1
Suspended	`NCT06083883` - Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1	Phase 1
Terminated	`NCT05355753` - A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors	Phase 1/Phase 2
Withdrawn	`NCT05116800` - Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma	Phase 2